User: TahirAmin Topic: IP
Category: drugs :: india
Last updated: May 30 2018 23:47 IST RSS 2.0
 
1 to 20 of 6,210    
Gap in regulating biotech drug copies prompts WHO to step in 30.5.2018 General News
LONDON (Reuters) - Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike - but uneven regulation has created a lopsided market.
Also found in: [+]
AstraZeneca opens another medicines development centre 30.5.2018 General News
Bio-pharmaceutical company AstraZeneca officially opened its new Global Medicines Development (GMD) centre here today. The unit is one of AstraZeneca's nine GMD centres that the company has around the world that transforms breakthrough molecules into medicines and monitors their use and safety, the company said in a press release. With this opening, India would now play an even bigger role in AstraZeneca's global operations, the release said. The GMD Bengaluru team would focus on supporting AstraZeneca's medicines which covers treatments across a range of therapies, including oncological, respiratory and cardiovascular and metabolic diseases, it said. GMD Bengaluru plays a key role supporting 51 of AstraZenecas mature brands which are used by patients around the world. Last year, the team recruited scientific experts in the fields of regulatory science, clinical, and patient safety, and has grown from 30 to 70 people. The expansion would see a further increase to more ...
Also found in: [+]
Sun Pharma warns U.S. pricing pressure to hit 2019 profit 25.5.2018 General News
(Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Friday it expects its 2019 revenue to come in short of analysts' expectations due to pricing pressure in its main market, the United States.
Also found in: [+]
CSIR bags the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category 24.5.2018 Govt of india: PIB
Council of Scientific & Industrial Research has been awarded the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category. This award yet again recognizes CSIR as the top innovator.
Also found in: [+]
CCI approves USD 66 bn Bayer-Monsanto deal 22.5.2018 General News
Fair trade regulator CCI has approved the German giant Bayer's proposed USD 66 billion acquisition of US-based biotech firm Monsanto, subject to certain modifications to the long-pending deal. The approval to the deal, announced in September 2016, assumes significance in the wake of Monsanto facing opposition from various quarters within India over promotion of genetically modified crops, as also over royalty and patent issues. The clearance from the Competition Commission of India (CCI) is one of the several regulatory approvals required by Bayer in various countries to close the deal. Announcing its approval today, the CCI tweeted that it has cleared "acquisition of Monsanto by Bayer AG, subject to compliance of certain modifications". Mergers and acquisitions beyond a certain threshold require approval of the CCI. India is one of the 30 countries whose approval is needed for the merger of worldwide operations of the two companies. The major approvals still required are from the US .
Also found in: [+]
Trinity League India standalone net profit rises 293.75% in the March 2018 quarter 17.5.2018 General News
Sales rise 440.00% to Rs 0.81 crore
Also found in: [+]
Ayushman Bharat may help patients access life-saving drugs 16.5.2018 Rediff: Top Stories (India)
'We have often heard the mythical argument that patents block access to life-saving drugs, but only 5% of medicines from multinational companies are under patent protection in India.''Where these patented products are beyond the reach of Indian patients, the companies have programmes to facilitate access to their drugs, for free or for a fraction of the price,' points out Ranjana Smetacek, former director general, Organisation of Pharmaceutical Producers of India.
Also found in: [+]
Reward innovation 12.5.2018 Hindu: Internet
A robust intellectual property rights (IPR) framework, with suitable enforcement systems, is critical to support India’s efforts to be a global leade
Also found in: [+]
'Indian IP and liabilities law barrier to pharma R&D investment' 10.5.2018 General News
India's intellectual property regulations and liabilities laws pose a major barrier to foreign companies, specially from the US, that prevents them from increasing their footprint in the country's huge market, pharma sector leaders have said. Andrew Plump, chief medical and scientific officer of Takeda Pharmaceuticals, a major Japanese drugmaker, said his company has a very limited presence in India. "But it is open to increase its footprint in India, with the improvement in IP protection laws and those related to liabilities," Plump said. "I think more and more there's an intent in India to try to open up its doors. I think if that happens, and if it facilitates entry of innovative patent protected pharmaceuticals you will see value driven companies coming into India," Plump told PTI on the sidelines of the 12th annual biopharma and healthcare summit here. "Historically it (IP sector regulations and liabilities law) has been not just a hindrance but a barrier and impediment (for the .
Also found in: [+]
Prabhu urges pharma firms to do more R&D, develop new markets 8.5.2018 All News-IANS Stories
Indian pharmaceutical companies need to increase R&D investments and develop new markets in order to boost their exports, Commerce Minister Suresh Prabhu said on Tuesday.
Also found in: [+]
USTR again places India on ‘watch list’ 28.4.2018 Hindu: Policy & Issues
New Delhi: The Office of the U.S. Trade Representative has once again placed India on ‘Priority Watch List’ in its annual Special 301 Report on the s
Also found in: [+]
The elephant in the Patent Office 27.4.2018 Hindu: Home
Patents for trivial improvements on drugs, though statutorily barred, are routinely granted
Also found in: [+]
US places India again on priority watch list on IP protection 27.4.2018 General News
India would continue to remain on the US' Priority Watch List for longstanding challenges in its IP framework and lack of sufficient measurable progress, the USTR said, alleging that the country remains one of the world's most challenging major economies in the area. In its latest 2018 Special 301 Report, the US Trade Representative has placed 12 countries on its Priority Watch List. In addition to India, other countries on the list are Algeria, Argentina, Canada, Chile, China, Colombia, Indonesia, Kuwait, Russia, Ukraine, and Venezuela. The Intellectual Property (IP) issues in these countries will be the subject of intense bilateral engagement during the coming year, the USTR said in its report. Special 301 Report identifies US trading partners that do not adequately or effectively protect and enforce IP rights or otherwise deny market access to its innovators and creators that rely on protection of their IP rights. India "remains on the Priority Watch List this year for longstanding
Also found in: [+]
Big opportunities in defence, mfg, pharma to boost India, UK investments: UKIBC 20.4.2018 General News
A huge potential exists in sectors including manufacturing, defence, pharmaceuticals and start-ups to boost investments between India and the UK, a report by the UK India Business Council (UKIBC) has said. "Exciting trends in digitisation, including the onset of 4-IR (industrial revolution), are creating new investment opportunities. The rise of smart cities, the potential of fintech, along with the start-up culture, has generated areas where investment potential is exponential but as yet largely untapped," the report said. It said that industry revolution would impact virtually all sectors of the economies of India and the UK; and growing usage of artificial intelligence, robotics, Internet of Things, blockchain, big data and 3D printing open new opportunities for collaborations and investment in both countries. Making a case for early negotiations for a free trade agreement, it said that the current business environment in both the countries is conducive for mutual investment ...
Also found in: [+]
Pharma formulators to invest in growing OTC market: Report 18.4.2018 General News
Indian pharmaceutical formulators are expected to continue to make investments in consumer healthcare, wellness products and traditional OTC product categories to grow domestic non-prescription business through organic and inorganic routes, a report said. These investments would be driven by the need to further diversify the domestic prescription business, India Ratings and Research (Ind-Ra) said in its report. According to Business Monitor International (BMI), India's non-prescription or OTC market contributes around 14.5 per cent to the total pharmaceutical sales and is expected to grow to USD 4.2 billion at a CAGR of 8.8 per cent over 2017-2022. The growth is likely to be driven by limited household affordability for frequent clinical visits, convenience of direct purchase and growing preference for self-medication for minor ailments, it said. Investments by Indian formulators are likely to be in consumer healthcare and wellness products, apart from the traditional ..
Also found in: [+]
Torrent Pharmaceuticals draws up plan to reduce dependence on US 18.4.2018 Business Standard: News Now
Company to draw 47% of revenue and 67% of Ebitda from Indian business by FY20
Also found in: [+]
Glenmark Pharmaceuticals gets final approval for Tacrolimus Ointment, 0.1% 18.4.2018 General News
From USFDA
Also found in: [+]
Children in polluted cities at increased risk of Alzheimer's, reveals study 14.4.2018 Business Standard: News Now
The findings indicated that Alzheimer's starts in early childhood
Also found in: [+]
U.S. wants patent form recall 14.4.2018 Hindu: Fitness
Submission on interpretation of a domestic patent law raises eyebrows
Also found in: [+]
Canadian pharmacy to be fined millions for illegal imports 13.4.2018 General News
An online pharmacy that bills itself as Canada's largest is expected to be fined USD 34 million today for importing counterfeit cancer drugs and other unapproved pharmaceuticals into the United States, a sentence that one advocacy group called too light for such a heinous crime. Canada Drugs has filled millions of prescriptions by offering itself as a safe alternative for patients to save money on expensive drugs, and its founder, Kristian Thorkelson, has been hailed as an industry pioneer for starting the company in 2001. But US prosecutors say Canada Drugs' business model is based entirely on illegally importing unapproved and misbranded drugs not just from Canada, but from all over the world. The company has made at least USD 78 million through illegal imports, including two that were counterfeit versions of the cancer drugs Avastin and Altuzan that had no active ingredient, prosecutors said. After more than two years of struggling to get the international company to appear in US ..
Also found in: [+]
1 to 20 of 6,210